Scientists have discovered that DNA mutations acquired throughout life in immune cells may be a hidden driver of thyroid autoimmune diseases like Hashimoto's and Graves' disease. Using advanced sequencing techniques, researchers from the Wellcome Sanger Institute and Cambridge University identified previously undetectable mutations in B cells (a type of white blood cell) that disable the immune system's natural "brakes," allowing it to attack the thyroid gland .

What Are Somatic Mutations and Why Do They Matter for Your Thyroid?

Somatic mutations are DNA changes that occur in individual cells over time and are not inherited from parents. Unlike genetic mutations you're born with, these mutations accumulate silently throughout your life. For decades, scientists suspected these mutations might contribute to autoimmune diseases, but the technology to detect them didn't exist until recently .

The research team used a cutting-edge technique called NanoSeq, which can detect rare mutations invisible to traditional DNA sequencing methods. When they examined thyroid tissue from patients with Hashimoto's thyroiditis and Graves' disease, they found something striking: many B cells had developed inactivating mutations in two critical immune-checkpoint genes called TNFRSF14 and CD274 (also known as PDL1). These genes normally act as "off switches" that prevent the immune system from attacking the body's own tissues .

What surprised researchers most was the scale of the problem. Some B cell clones had accumulated as many as six driver mutations over many years, silently building up changes in DNA before symptoms appeared. This pattern of multiple mutations accumulating over time had previously only been observed in cancer .

How Do These Mutations Lead to Thyroid Disease?

When immune-checkpoint genes like TNFRSF14 and CD274 become inactivated, the immune system loses its ability to regulate itself properly. Normally, these genes tell immune cells when to stop attacking. Without them, B cells continue mounting an attack on thyroid tissue even when there's no actual threat. Interestingly, when researchers artificially inactivate these same genes in laboratory studies or during cancer immunotherapy, thyroid autoimmunity develops. The fact that these mutations occur naturally in autoimmune patients suggests they play a direct role in disease development .

"Our study suggests that somatic mutations in immune cells may play an important role in autoimmune disease, an idea first proposed in the 1950s that we have lacked the techniques to investigate. Now that we have NanoSeq, which we developed in the last few years, we can study somatic mutations with ultra-high accuracy and explore their contribution to autoimmune diseases, not just cancer," said Dr. Andrew Lawson, co-first author at the Wellcome Sanger Institute.

Dr. Andrew Lawson, Co-First Author at the Wellcome Sanger Institute

The research team also found that these mutations occur in multiple independent clones of B cells within each patient. This means the mutations aren't a one-time accident but rather a pattern that develops repeatedly across different immune cells, suggesting a systematic breakdown in immune regulation .

What This Means for Thyroid Treatment and Diagnosis

Currently, thyroid autoimmune diseases are treated by broadly suppressing the entire immune system with medications. While this approach can reduce thyroid antibodies, it leaves patients vulnerable to infections and other complications. If these findings are confirmed through further research, they could enable doctors to develop more targeted treatments that address the specific mutations driving disease in individual patients .

"Autoimmune diseases are currently treated by broadly suppressing the immune system, which can leave patients vulnerable to infections as well as a long list of other complications. If these findings are confirmed, they could eventually enable more precise diagnoses and treatments leading to better patient outcomes," noted Dr. Pantelis Nicola, co-first author formerly of the Wellcome PhD Programme for Clinicians in Cambridge and currently a clinical lecturer at The Christie in Manchester.

Dr. Pantelis Nicola, NIHR Clinical Lecturer at The Christie in Manchester

The implications extend beyond just thyroid disease. The research team has already begun seeing similar patterns in other autoimmune conditions, though these findings remain preliminary. This suggests that somatic mutations in immune cells may be a common mechanism underlying multiple autoimmune diseases, not just thyroid-specific conditions .

Steps to Understanding Your Thyroid Autoimmunity Risk

• Know Your Family History: While these somatic mutations are acquired during life rather than inherited, having a family history of autoimmune disease increases your baseline risk of developing thyroid autoimmunity. Ask relatives about Hashimoto's, Graves' disease, or other autoimmune conditions.
• Monitor Your Symptoms Over Time: Thyroid autoimmunity develops gradually as mutations accumulate. Fatigue, weight changes, temperature sensitivity, and mood changes that develop slowly over months or years warrant thyroid testing, even if previous tests were normal.
• Request Comprehensive Thyroid Testing: Standard TSH (thyroid-stimulating hormone) testing may not catch early autoimmune thyroid disease. Ask your doctor about testing for thyroid antibodies (TPO and thyroglobulin antibodies) if you have symptoms, as these indicate autoimmune activity before significant thyroid dysfunction develops.

The discovery of somatic mutations in thyroid autoimmunity represents a fundamental shift in how scientists understand these diseases. For nearly 70 years, researchers theorized that mutations in immune cells might drive autoimmune disease, but lacked the tools to prove it. Now, with advanced sequencing technology, that theory has become reality. As Dr. Inigo Martincorena, senior author at the Wellcome Sanger Institute, explained, "For decades, researchers have wondered whether somatic mutations might contribute to autoimmune disease, but evidence has been elusive. Our findings suggest this process is far more widespread than we anticipated" .

While further research is needed to confirm whether these mutations are the root cause of autoimmune thyroid disease or contribute to its progression over time, the findings open a new frontier in precision medicine. Instead of treating all thyroid autoimmune patients the same way, doctors may eventually be able to identify which specific mutations are driving disease in each patient and tailor treatment accordingly. For the millions of people living with Hashimoto's and Graves' disease, this research offers hope that more effective, personalized treatments may be on the horizon.